Home > Healthcare > Drug Device Combination > Drug Filled Devices > U.S. Hormone Replacement Therapy Market

U.S. Hormone Replacement Therapy Market Analysis

  • Report ID: GMI7407
  • Published Date: Nov 2023
  • Report Format: PDF

U.S. Hormone Replacement Therapy Market Analysis

U.S. Hormone Replacement Therapy Market, By Product, (USD Billion)

To understand key trends  
Download Free Sample
 

Based on product, the market is segmented into estrogen & progesterone replacement therapy, thyroid replacement therapy, growth hormone replacement therapy, parathyroid hormone replacement therapy, and testosterone replacement therapy. The estrogen & progesterone replacement therapy segment accounted for highest market share of 55.3% in 2022 and is expected to reach USD 7.5 billion by 2032.
 

  • Estrogen and progesterone replacement therapy has a well-established track record of effectiveness in managing menopausal symptoms and can be used for postmenopausal osteoporosis treatment. It is considered one of the most effective treatments for addressing these health concerns, which enhances its popularity and market share.
     
  • The efficacy and safety of estrogen and progesterone replacement therapy are supported by a substantial body of clinical research and scientific evidence.
     

Based on route of administration, the U.S. hormone replacement therapy market is classified into oral, parenteral, and other routes of administration. In 2022, the oral segment secured the largest market share at 43.5% and is anticipated to exhibit substantial growth from 2023 to 2032.
 

  • This growth is attributed to factors like its non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.
     
  • Oral HRT ensures a consistent dosing regimen, simplifying treatment management for both patients and healthcare providers. The steady and predictable delivery of hormones facilitates monitoring and adjustment of treatment plans.
     

By disease type, the U.S. hormone replacement therapy market is segmented into menopause, hypothyroidism, growth hormone deficiency, hypoparathyroidism, male hypogonadism, and other disease type. In 2022, the menopause segment accounted for highest market share of 50.5% and is anticipated to witness growth at 7 % during the analysis period.
 

  • Menopause is characterized by a range of symptoms, including hot flashes, night sweats, mood swings, sleep disturbances, vaginal dryness, and more. These symptoms can be disruptive and significantly impact a woman's quality of life. HRT provides an effective means of alleviating these symptoms, leading to improved comfort and well-being.
     
  • Thus, the large share of the menopause segment can be attributed to the higher usage of HRT for the management of its symptoms, the increasing prevalence of menopause, and the growing availability of various formulation for management of its symptoms.
     
U.S. Hormone Replacement Therapy Market, By Distribution Channel (2022)

To understand key market trends  
Download Free Sample
 

Based on distribution channel, the U.S. hormone replacement therapy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held highest business share of 57.2%.
 

  • Hospitals are primary healthcare institutions where patients with various medical conditions, including those requiring HRT, receive comprehensive care.
     
  • Further, hospital pharmacies are well equipped to provide the highest quality of care and contribute significantly to the utilization of HRT.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. hormone replacement therapy industry size was USD 6.9 billion in 2022 and is anticipated to be valued at USD 13.4 billion from 2023-2032 due to the aging population and the significant number of women reaching menopausal stages.

The oral route of administration recorded 43.5% share of the market in 2022 driven by non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.

The hospital pharmacies distribution channel segment held 57.2% of the U.S. hormone replacement therapy market share in 2022 due to the presence of the highest quality of care.

Some of the major hormone replacement therapy firms in the U.S. include Eli Lilly and Company, Bayer AG, Pfizer Inc., Viatris, Inc., Noven Pharmaceuticals, Inc., Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd.

U.S. Hormone Replacement Therapy Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 60
  • Countries covered: 1
  • Pages: 91
 Download Free Sample